Clinical trial
A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor
Name
NSH 1158
Description
Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of patients are cured, 1/3 are dependent on long term immunosuppression, and the other 1/3 relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical donor for transplantation has good response rates and significantly lower rates of acute and chronic GVHD.
Trial arms
Trial start
2016-09-09
Estimated PCD
2025-08-31
Trial end
2026-08-31
Status
Recruiting
Phase
Early phase I
Treatment
Fludarabine
30 mg/m2 IV QD x 5 days (Days -6 to -2)
Arms:
Flu/Cy/TBI
Cyclophosphamide
14.5 mg/kg/day IV x 2 doses (Days -6 \& -5)
Arms:
Flu/Cy/TBI
Total Body Irradiation
300 cGy x1 dose (Day -1)
Arms:
Flu/Cy/TBI
Other names:
TBI
Rabbit ATG
1.5 mg/kg/day x 3 days (Days -3 to -1)
Arms:
Flu/Cy/TBI
Cyclophosphamide
Post-transplant: 50 mg/kg IV QD (Day +3 to +4)
Arms:
Flu/Cy/TBI
Size
20
Primary endpoint
Demonstrate sustained engraftment after T-cell replete HLA-mismatched haploidentical bone marrow transplantation by collecting chimerism tests monthly following transplant
2 years
Eligibility criteria
Inclusion Criteria:
* Availability of 3/6 - 5/6 matched (HLA-A, B, DR) related donor who must have negative HLA cross-match in the host vs. graft direction
* Age \<= 65 years for previously treated and \<= 75 years for previously treated patients
* KPS \>= 70%
* Aplastic Anemia that meets the following criteria:
Peripheral Blood (must fulfill 2 of 3):
* \<500 PMN/mm3
* \<20,000 platelets
* absolute reticulocyte count \<40,000/microL
Bone Marrow (must be either):
* markedly hypocellular (\<25% of normal cellularity)
* moderately hypocellular with 70% non-myeloid precursors and patient meets peripheral blood criteria above
Exclusion Criteria:
* poor cardiac function (LVEF \<40%)
* poor pulmonary function (FEV1 \& FVC \<50% predicted)
* poor liver function (bili \>= 2mg/dL)
* poor renal function (creatinine \>= 2.0mg/dL or creatinine clearance \<40mL/min)
* prior allogeneic transplant
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}}
Updated at
2024-04-15
1 organization
3 products
1 drug
1 indication
Organization
Northside HospitalProduct
FludarabineIndication
Aplastic AnemiaProduct
CyclophosphamideProduct
Rabbit ATGDrug
cyclophosphamide